Alpha 2.0
Login Register
» Authors » Corinna Ernst

Corinna Ernst

Explore the profile of Corinna Ernst including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 34
Citations 816
Followers 0
Related Specialties
Oncology
Genetics
Endocrinology
Top 10 Co-Authors
Eric Hahnen
Rita K Schmutzler
Jan Hauke
Christoph Engel
Barbara Wappenschmidt
Julika Borde
Janine Altmuller
Holger Thiele
Peter Nurnberg
Nana Weber-Lassalle
Published In
Cancers (Basel)
JAMA Netw Open
J Med Genet
Euro Surveill
Breast
Affiliations
Soon will be listed here.
Recent Articles
1.
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
Richters L, Gluz O, Weber-Lassalle N, Christgen M, Haverkamp H, Kuemmel S, et al.
JAMA Netw Open . 2025 Feb; 8(2):e2461639. PMID: 40009381
Importance: Subgroup definitions for possible deescalation of neoadjuvant cancer treatment are urgently needed in clinical practice. Objective: To investigate the effect of BRCA1 and/or BRCA2 tumor pathogenic variants (tPVs) by...
2.
Limitations in next-generation sequencing-based genotyping of breast cancer polygenic risk score loci
Baumann A, Ruckert C, Meier C, Hutschenreiter T, Remy R, Schnur B, et al.
Eur J Hum Genet . 2024 Jun; 32(8):987-997. PMID: 38907004
Considering polygenic risk scores (PRSs) in individual risk prediction is increasingly implemented in genetic testing for hereditary breast cancer (BC) based on next-generation sequencing (NGS). To calculate individual BC risks,...
3.
High vaccine effectiveness against severe COVID-19 outcomes and population preventable fraction during the Omicron era in Luxembourg: A nationwide retrospective risk factor analysis
Bejko D, Ernst C, Vergison A, Stranges S, Zeegers M, Mossong J
Vaccine . 2024 Jun; 42(22):126011. PMID: 38825555
Background: Luxembourg experienced major consecutive SARS-CoV-2 infection waves due to Omicron variants during 2022 while having achieved a high vaccination coverage in 2021. We investigated the risk factors associated to...
4.
Population-specific validation and comparison of the performance of 77- and 313-variant polygenic risk scores for breast cancer risk prediction
Hovhannisyan M, Zemankova P, Nehasil P, Matejkova K, Borecka M, cerna M, et al.
Cancer . 2024 May; 130(17):2978-2987. PMID: 38718029
Background: The polygenic risk score (PRS) allows the quantification of the polygenic effect of many low-penetrance alleles on the risk of breast cancer (BC). This study aimed to evaluate the...
5.
Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations
Schouten P, Schmidt S, Becker K, Thiele H, Nurnberg P, Richters L, et al.
JAMA Netw Open . 2024 Apr; 7(4):e245552. PMID: 38592722
Importance: Testing for homologous recombination deficiency is required for the optimal treatment of high-grade epithelial ovarian cancer. The search for accurate biomarkers is ongoing. Objective: To investigate whether progression-free survival...
6.
A deep intronic recurrent CHEK2 variant c.1009-118_1009-87delinsC affects pre-mRNA splicing and contributes to hereditary breast cancer predisposition
Zemankova P, cerna M, Horackova K, Ernst C, Soukupova J, Borecka M, et al.
Breast . 2024 Mar; 75:103721. PMID: 38554551
Germline CHEK2 pathogenic variants confer an increased risk of female breast cancer (FBC). Here we describe a recurrent germline intronic variant c.1009-118_1009-87delinsC, which showed a splice acceptor shift in RNA...
7.
Implementing mainstream genetic counseling within the area-wide network of the German Consortium Hereditary Breast and Ovarian Cancer (GC-HBOC): Satisfaction of primary care providers with the provided state-of-the-art training by the Cologne Center
Herold N, Bredow K, Ernst C, Tuchler A, Blumcke B, Waha A, et al.
J Genet Couns . 2024 Feb; 33(1):206-215. PMID: 38351721
The German Cancer Society (Deutsche Krebsgesellschaft DKG) has published a position paper to address the challenges of cancer patient care in the era of genomic medicine. The German Consortium Hereditary...
8.
Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg
Ernst C, Bejko D, Gaasch L, Hannelas E, Kahn I, Pierron C, et al.
Euro Surveill . 2024 Jan; 29(4). PMID: 38275017
After Luxembourg introduced nirsevimab immunisation against respiratory syncytial virus (RSV), estimated neonatal coverage was 84% (1,277 doses/1,524 births) in 2023. That year, paediatric RSV-related hospitalisations, especially concerning infants < 6 ...
9.
Clinical implications of incorporating genetic and non-genetic risk factors in CanRisk-based breast cancer risk prediction
Tuchler A, de Pauw A, Ernst C, Anota A, Lakeman I, Dick J, et al.
Breast . 2023 Dec; 73:103615. PMID: 38061307
Background: Breast cancer (BC) risk prediction models consider cancer family history (FH) and germline pathogenic variants (PVs) in risk genes. It remains elusive to what extent complementation with polygenic risk...
10.
ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk
Stolarova L, Kleiblova P, Zemankova P, Stastna B, Janatova M, Soukupova J, et al.
Clin Cancer Res . 2023 Jul; 29(16):3037-3050. PMID: 37449874
Purpose: Germline pathogenic variants in CHEK2 confer moderately elevated breast cancer risk (odds ratio, OR ∼ 2.5), qualifying carriers for enhanced breast cancer screening. Besides pathogenic variants, dozens of missense...